WO2004048342A1 - 1−[2−(ベンズイミダゾール−2−イルチオ)エチル]ピペラジン又はその塩の製造法 - Google Patents
1−[2−(ベンズイミダゾール−2−イルチオ)エチル]ピペラジン又はその塩の製造法 Download PDFInfo
- Publication number
- WO2004048342A1 WO2004048342A1 PCT/JP2003/015154 JP0315154W WO2004048342A1 WO 2004048342 A1 WO2004048342 A1 WO 2004048342A1 JP 0315154 W JP0315154 W JP 0315154W WO 2004048342 A1 WO2004048342 A1 WO 2004048342A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ethyl
- compound
- ylthio
- piperazine
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
Definitions
- the present invention relates to an intermediate for the production of an ACAT inhibitor.
- Achilles Coenzyme A Cholesterol Acsyltransferase (ACAT) is an enzyme that catalyzes the synthesis of cholesterol into cholesterol esters and plays an important role in the metabolism of cholesterol and its absorption in the gastrointestinal tract.
- ACAT Achilles Coenzyme A Cholesterol Acsyltransferase
- an azole compound having a cyclic diamine structure in particular, the following formula ( 7):
- Ar represents an aryl group or a heteroaryl group which may have a substituent.
- the cyclic diamine compound represented by or a salt thereof has few side effects, is highly water-soluble, and It has been found that it has excellent oral absorbability and is useful as a therapeutic agent for hyperlipidemia and arteriosclerosis, and has previously filed an international application (WO 98/54153 pamphlet).
- compound (7) is produced in the following 5 steps using 1- (2-hydroxyethyl) piperazine (6) as a starting material.
- step-a the target compound (1 a) is a simple purification method. Purification is difficult 3) Due to the difficulty of distillation purification, it is not easy to obtain the highly anhydrous compound (la) required in step b) 4)
- step 1c the mesyl form of the raw material The stability of (2a) is poor, and it is difficult to reproduce the yield of a small-scale synthesis when synthesizing on a large scale.
- Step d if the yield of the deprotection reaction is not sufficient There were problems such as not. Disclosure of the invention
- the present invention provides an industrially advantageous production method of an intermediate [11- (benzimidazo-l-2-ylthio) ethyl] pidazine or a salt thereof (5), which is an intermediate for producing a cyclic diamine compound (7) or a salt thereof.
- the purpose is to provide the law.
- the present invention provides a compound represented by the formula (2) by converting a hydroxyl group of 11-formyl-41- (2-hydroxyethyl) piperazine represented by the formula (1) into a leaving group, Is reacted with 2-mercaptobenzimidazole (3) in the presence of a base to give the formula (
- the present invention provides a method for producing 1- [2- (benzimidazole-2-ylthio) ethyl] pirazine or a salt thereof represented by the following formula:
- 1_ [2- (benzimidazo-l-2-ylthio) ethyl] piperazine or a salt thereof (5) can be efficiently produced, and thus is useful as a medicine.
- the cyclic diamine compound (7) or a salt thereof can be industrially advantageously produced in a stable yield as compared with the conventional method.
- the leaving group represented by “X” means a sulfonyloxy group or a group which can be easily substituted such as a halogen atom, for example, methanesulfonyloxy, benzenesulfonyloxy, Examples include sulfonyloxy groups such as methanesulfonyloxy, ethanesulfonyloxy, propanesulfonyloxy, and p_toluenesulfonyloxy, and halogen atoms such as chlorine, bromine, and iodine. preferable.
- the compound (5) of the present invention can form an acid addition salt.
- Examples of such a salt include inorganic salts such as hydrochloride, sulfate, nitrate and phosphate, and methanesulfonate. And organic acid salts such as maleate, fumarate, citrate and trifluoroacetate.
- the compound (5) includes not only unsolvated compounds but also hydrates or solvates to which solvents used during production and purification, such as water and alcohol, have been added.
- Examples of the method for converting the hydroxyl group of the compound (1) into a leaving group include a method of sulfonylating the hydroxyl group and a method of converting it to a halogen atom.
- the sulfonylation may be usually carried out by reacting compound (1) with a sulfonic acid chloride or sulfonic anhydride in a solvent at 0 ° C to room temperature in the presence of a base.
- sulfonic acid chloride or sulfonic anhydride examples include alkylsulfonic acids such as methanesulfonic acid and ethanesulfonic acid, and arylsulfonic acids such as benzenesulfonic acid and p-toluenesulfonic acid.
- triethylamine, N, N-diisopropylethylamine, pyridine, 4-dimethylaminopyridine and the like can be used, and the solvent is chloroform, methylene chloride, acetonitrile, tetrahydrofuran, ethyl acetate, Benzene, toluene, dimethylformamide and the like can be used.
- the conversion of a hydroxyl group to a halogen atom can be performed, for example, by adding phosphorus oxychloride, phosphorus pentachloride, dichlorotriphenylphosphine, triphenylphosphine dibromide, triphenylphosphite dichloride, triphenylphosphite dibromide.
- Chlorinating or brominating agents such as phosphorus tribromide, thionyl chloride, triphenylphosphine and carbon tetrachloride, triphenylphosphine and carbon tetrabromide, methanesulfonyl chloride and 4-dimethylaminopyridine, It is preferable to carry out the reaction at 0 to 120 ° C. without solvent or in a solvent such as dichloromethane, chloroform, dichloroethane, pyridine and tetrahydrofuran.
- Process-2 The reaction between compound (2) and 2-mercaptobenzimidazole (3) can be carried out in a solvent in the presence or absence of a base and a catalyst.
- soot for example, dimethylformamide, dimethylsulfoxide, methylene chloride, chloroform, tetrahydrofuran, toluene, acetone, acetonitrile and the like can be used alone or in combination.
- the base examples include alkali metal hydroxides such as sodium hydroxide and potassium hydroxide; alkali metal carbonates such as sodium carbonate and carbon dioxide; sodium hydrogen carbonate such as sodium hydrogen carbonate and lithium hydrogen carbonate.
- Inorganic bases such as metals and organic bases such as pyridine, triethylamine, N, N-diisopropylethylamine, N-methylmorpholine, N, N-dimethylaniline and the like can be used.
- the catalyst examples include crown ethers such as 18-crown-6, tetrabutylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium bromide, tetrabutylammonium hydrogen sulfate, benzyl trimethylammonium bromide, etc. And quaternary ammonium salts of which are preferred. Among them, 18-crown-16 is preferred.
- the reaction may be carried out generally at 0 to 120 ° C., preferably 20 to 100 ° C., for 1 to 12 hours, preferably 1 to 3 hours.
- the target compound (4) has good crystallinity and can be easily purified by crystallization. In addition, even if this reaction is performed on an industrial scale, the reaction on a small scale is reflected, and the target compound can be obtained in high yield and high purity.
- the elimination of the formyl group is preferably carried out by adding an acid to compound (4) in a solvent at 0 ° C. to 100 t.
- Solvents include methanol, ethanol, isopropyl alcohol And benzene, toluene, ethyl acetate and the like, or a water-containing solvent thereof.
- As the acid hydrochloric acid, sulfuric acid and the like can be used.
- the compound (5) thus obtained or a salt thereof is introduced with a bromo group (8) into an amino group in the presence of a base in the same manner as in the method described in Patent Document 1 to give a cyclic diamine compound ( 7) or a salt thereof can be produced efficiently.
- the starting material for the production method of the present invention 1-formyl-14- (2-hydroxyethyl) piperazine (1)
- Compound (1) is obtained by reacting 1-formylpidazine with ethylene oxide, or reacting 1-formylpidazine with ethylenehalohydrin or its hydroxyl-protected compound in the presence of a base (in the case of a protected compound, The reaction can also be carried out together with the elimination reaction of the protecting group).
- the production method of the present invention using 1-formyl-14_ (2-hydroxyethyl) piperazine is based on the conventional method using 1- (tert-butoxycarbonyl) -4-1- (2-hydroxyshethyl) pirazine.
- the yield was improved (Steps 1 and 2) and the purification method was simplified (Step 2).
- the yield decreased when the scale was increased.
- the yield of compound (4a) using 2 g of compound (la) was 64%, whereas the yield of compound (4a) was 64%.
- the yield of compound (4a) when using 50 g of (la) was 26%).
- this was not the case, and similar results were obtained on an industrial scale as on a small scale. Obtained.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03775913A EP1566381B1 (en) | 2002-11-28 | 2003-11-27 | Process for production of 1- 2-(benzimidazol-2-yl- thio)ethyl piperazine or salts thereof |
AT03775913T ATE448208T1 (de) | 2002-11-28 | 2003-11-27 | Verfahren zur herstellung von 1-2-(benzimidazol-2-yl-thio)ethyl piperazin bzw. salzen davon |
AU2003284459A AU2003284459A1 (en) | 2002-11-28 | 2003-11-27 | Process for production of 1-(2-(benzimidazol-2-yl- thio)ethyl)piperazine or salts thereof |
DK03775913.1T DK1566381T3 (da) | 2002-11-28 | 2003-11-27 | Fremgangsmåde til fremstilling af 1- 2-(benzimidazol-2-ylthio)ethyl-piperazin eller salte deraf |
DE60330040T DE60330040D1 (de) | 2002-11-28 | 2003-11-27 | Verfahren zur herstellung von 1-2-(benzimidazol-2-yl-thio)ethyl piperazin bzw. salzen davon |
JP2004555060A JP4571505B2 (ja) | 2002-11-28 | 2003-11-27 | 1−[2−(ベンズイミダゾール−2−イルチオ)エチル]ピペラジン又はその塩の製造法 |
US10/535,705 US7214796B2 (en) | 2002-11-28 | 2003-11-27 | Process for production of 1-[2-(benzimidazol-2-yl-thio)ethyl]piperazine or salts thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-346114 | 2002-11-28 | ||
JP2002346114 | 2002-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004048342A1 true WO2004048342A1 (ja) | 2004-06-10 |
Family
ID=32376044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/015154 WO2004048342A1 (ja) | 2002-11-28 | 2003-11-27 | 1−[2−(ベンズイミダゾール−2−イルチオ)エチル]ピペラジン又はその塩の製造法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7214796B2 (ja) |
EP (1) | EP1566381B1 (ja) |
JP (1) | JP4571505B2 (ja) |
AT (1) | ATE448208T1 (ja) |
AU (1) | AU2003284459A1 (ja) |
DE (1) | DE60330040D1 (ja) |
DK (1) | DK1566381T3 (ja) |
ES (1) | ES2334221T3 (ja) |
PT (1) | PT1566381E (ja) |
WO (1) | WO2004048342A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1767527A4 (en) * | 2004-06-30 | 2009-11-11 | Kowa Co | PROCESS FOR PRODUCING CYCLIC DIAMINE DERIVATIVE |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3585194A (en) * | 1967-08-11 | 1971-06-15 | Rohm & Haas | Formamide-containing hydroxy compounds |
DE2209853A1 (ja) * | 1971-03-01 | 1972-09-07 | ||
EP0334818A1 (en) * | 1988-03-25 | 1989-09-27 | DOMPE' FARMACEUTICI S.p.A. | Pharmacologically active alkylthiobenz imidazole derivatives and process for the preparation thereof |
US5068264A (en) * | 1989-04-27 | 1991-11-26 | Bayer Aktiengesellschaft | Formylpiperazinyl-(meth)acrylic acid derivatives for treatment of collagen |
WO1998054153A1 (fr) * | 1997-05-26 | 1998-12-03 | Kowa Company, Ltd. | Nouveaux composes de diamine cycliques et medicament contenant ces composes |
WO2003057675A1 (fr) * | 2001-12-28 | 2003-07-17 | Kowa Co., Ltd. | Procedes pour produire des composes de diamine cyclique ou des sels de ceux-ci |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6969711B2 (en) | 1997-05-26 | 2005-11-29 | Kowa Company, Ltd. | Cyclic diamine compounds and medicine containing the same |
EP1571144A4 (en) | 2002-12-12 | 2007-08-01 | Kowa Co | HYDROXYALKYLATED CYCLIC DEDIAMINE COMPOUND |
-
2003
- 2003-11-27 US US10/535,705 patent/US7214796B2/en not_active Expired - Fee Related
- 2003-11-27 AT AT03775913T patent/ATE448208T1/de active
- 2003-11-27 WO PCT/JP2003/015154 patent/WO2004048342A1/ja active Application Filing
- 2003-11-27 PT PT03775913T patent/PT1566381E/pt unknown
- 2003-11-27 DK DK03775913.1T patent/DK1566381T3/da active
- 2003-11-27 JP JP2004555060A patent/JP4571505B2/ja not_active Expired - Fee Related
- 2003-11-27 EP EP03775913A patent/EP1566381B1/en not_active Expired - Lifetime
- 2003-11-27 AU AU2003284459A patent/AU2003284459A1/en not_active Abandoned
- 2003-11-27 ES ES03775913T patent/ES2334221T3/es not_active Expired - Lifetime
- 2003-11-27 DE DE60330040T patent/DE60330040D1/de not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3585194A (en) * | 1967-08-11 | 1971-06-15 | Rohm & Haas | Formamide-containing hydroxy compounds |
DE2209853A1 (ja) * | 1971-03-01 | 1972-09-07 | ||
EP0334818A1 (en) * | 1988-03-25 | 1989-09-27 | DOMPE' FARMACEUTICI S.p.A. | Pharmacologically active alkylthiobenz imidazole derivatives and process for the preparation thereof |
US5068264A (en) * | 1989-04-27 | 1991-11-26 | Bayer Aktiengesellschaft | Formylpiperazinyl-(meth)acrylic acid derivatives for treatment of collagen |
WO1998054153A1 (fr) * | 1997-05-26 | 1998-12-03 | Kowa Company, Ltd. | Nouveaux composes de diamine cycliques et medicament contenant ces composes |
WO2003057675A1 (fr) * | 2001-12-28 | 2003-07-17 | Kowa Co., Ltd. | Procedes pour produire des composes de diamine cyclique ou des sels de ceux-ci |
Non-Patent Citations (1)
Title |
---|
ARZNEIM, FORSCH, vol. 12, 1962, pages 937 - 941 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004048342A1 (ja) | 2006-03-23 |
US7214796B2 (en) | 2007-05-08 |
EP1566381A1 (en) | 2005-08-24 |
AU2003284459A1 (en) | 2004-06-18 |
JP4571505B2 (ja) | 2010-10-27 |
EP1566381B1 (en) | 2009-11-11 |
US20060035906A1 (en) | 2006-02-16 |
EP1566381A4 (en) | 2006-11-02 |
DK1566381T3 (da) | 2010-01-25 |
ATE448208T1 (de) | 2009-11-15 |
ES2334221T3 (es) | 2010-03-08 |
PT1566381E (pt) | 2009-11-19 |
DE60330040D1 (de) | 2009-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8981095B2 (en) | Intermediate compounds and process for the preparation of lurasidone and salts thereof | |
WO2004110974A1 (en) | Matrix metalloproteinase inhibitors | |
US7563904B2 (en) | Synthesis intermediates useful for preparing zolmitriptan | |
JPH0610174B2 (ja) | アミノフエノ−ル誘導体 | |
WO2003057675A1 (fr) | Procedes pour produire des composes de diamine cyclique ou des sels de ceux-ci | |
WO2004048342A1 (ja) | 1−[2−(ベンズイミダゾール−2−イルチオ)エチル]ピペラジン又はその塩の製造法 | |
JP2018090551A (ja) | L−カルノシン誘導体またはその塩、及びl−カルノシンまたはその塩の製造方法 | |
JP2006505578A (ja) | 神経弛緩活性を有する5−(2−(4−(1,2ベンズイソチアゾール−3−イル)−1−ピペラジニル)エチル)−6−クロロ−1,3−ジヒドロ−2h−インドール−2−オンのアシル誘導体 | |
EP1339719B1 (fr) | Derives de benzimidazole, leur preparation et leur application en therapeutique | |
JP3207017B2 (ja) | ベンジルコハク酸誘導体の製造方法およびその製造中間体 | |
JP3207018B2 (ja) | ベンジルコハク酸誘導体の製造方法およびその製造中間体 | |
JPWO2004099136A1 (ja) | ピロリジン誘導体の製造方法 | |
US10906866B2 (en) | Process for the preparation of phenoxybenzamine | |
WO2004050654A1 (ja) | ピロリジン化合物の合成とその塩 | |
JP4886948B2 (ja) | ビフェニルエチルアミン誘導体およびその製造方法 | |
JPH06340658A (ja) | ベンゾイミダゾール誘導体 | |
WO2006003974A1 (ja) | 環状ジアミン誘導体の製造法 | |
US20070037854A1 (en) | Process for preparing sulfonamide-containing indole compounds | |
EP0082523A2 (en) | Intermediates for the preparation of 4-phenyl-1,3-benzodiazepins and methods for preparing the intermediates | |
JP2023553173A (ja) | 甲状腺ホルモン受容体β選択のアゴニスト化合物、その医薬組成物および用途 | |
JPS60169470A (ja) | 新規なフエニルピペラジン誘導体 | |
JPH07215968A (ja) | アゼラスチンの製造方法 | |
JP2004300101A (ja) | クロロピリミジン誘導体の製造方法 | |
JPS58164573A (ja) | 1−(4−クロロベンゾイル)−5−メトキシ−2−メチル−3−インド−ルアセトキシ酢酸類の製法 | |
EP1634879A1 (en) | Method of selectively introducing amino substituent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004555060 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003775913 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006035906 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10535705 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003775913 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10535705 Country of ref document: US |